Clomipramine has been the first drug for which specific therapeutic effects in Obsessive-Compulsive Disorder (OCD) have been demonstrated in empirical, open studies, with doses of circa 200 mg/day, after three months of treatment. Double-blind placebo-controlled studies have confirmed the efficacy of clomipramine in OCD. The antiobsessive effect of clomipramine is independent of the co-occurrence of depression. The effect-size (ES) of clomipramine in OCD calculated as the proportion of responders to clomipramine divided by the proportion of responders to placebo is larger than the effect-sizes (ESs) of the selective serotonin reuptake inhibitors (SSRIs).
|Translated title of the contribution||The effect-size of clomipramine in obsessive-compulsive disorder|
|Number of pages||13|
|Journal||Jornal Brasileiro de Psiquiatria|
|Publication status||Published - 1 Mar 1998|
- Obsessive-compulsive disorder